MARKET WIREReuters • 2h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
Why PHAR Stock slipped -1.06% Today — RQD Quant Desk Flash
$12.13 -1.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $12.08
Pharming Group N.V. ADS each representing 10 (PHAR) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $856.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PHAR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PHAR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Pharming Group N.V. ADS each representing 10 (NASDAQ: PHAR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $12.13 (-1.06% 1D, market cap $856.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PHAR ranks #229 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PHAR compare to CRVS and IVA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PHAR carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CRVS (Corvus Pharmaceuticals Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $860.6M) and IVA (Inventiva S.A. American Depository Shares) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $881.3M). Among the 5-stock peer group, PHAR leads on earnings multiple (N/A) while CRVS leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PHAR?
▼
For Pharming Group N.V. ADS each representing 10 (PHAR), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #229 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $12.08 (-0.38%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.6% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk B-
Each axis scored 0–20
12M PRICE TARGET CONE+0% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PHAR)Realized 20D OHLCV Swing Band: ±7.1%
Deterministic 5-Pillar Attribution (58/100 Composite)
🔍 WHY PHAR SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (26% of score)
FRED Regime × Technicals: 25% of 52W Range • RSI-14 at 70.1 (OVERBOUGHT (>70))
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$9.79-4.4% Next Q
50
Q2 (-2Q)Grade C-$9.36+19.7% Next Q
53
Q3 (-1Q)Grade C$11.20+8.3% Next Q
55
CurrentGrade D+$12.13+0% Hist 90D α
58
Trajectory: C- (50) → D+ (58)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the PHAR Bull Thesis Could Fail
Even with a 58/100 (D+) score, PHAR faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($10.71) or 200D SMA ($13.78) invalidates the momentum regime and cuts Target Base ($12.13) toward Bear Floor ($9.46).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PHAR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PHAR Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PHAR Stock slipped -1.06% Today — RQD Quant Desk Flash
Pharming Group N.V. ADS each representing 10 (PHAR) slipped -1.06% to $12.13, trading at 25% of its 52-week range ($9.11 – $21.34). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 25% of its 52-week range ($9.11 – $21.34) with RSI-14 at 70.1 (OVERBOUGHT (>70)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7.1% around $12.13 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $24.0M annual free cash flow.
Live PHAR Headlines & Catalysts
MARKET WIREReuters • 2h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
MARKET WIREReuters • 4h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 5h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 7h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 8h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 9h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 11h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PHAR)
- ✓Walkthrough of PHAR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PHAR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.62%📐 HORIZONTAL RANGE
2026-10-30O $12.20H $12.31L $12.09C $12.13VOL 14.0K
RES: $17.85SUP: $9.03SMA50: $10.71SMA200: $13.78
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PHAR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PHAR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PHAR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PHAR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PHAR)
Health Care Rank #229 of 1016
⚔️ CRVS vs PHAR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PHAR vs. CRVS, IVA, ALMS, OBX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Pharming Group N.V. ADS each representing 10 (PHAR) ranks #229 by composite RQD confidence (58/100, grade D+) and #381 by equity capitalization ($856.7M). Within this direct 5-issuer industry benchmark cohort, PHAR leads on earnings valuation at N/A trailing P/E, while CRVS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IVA currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with PHAR at 58/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PHAR
ACTIVE
Pharming Group N.V. ADS each representing 10 | D+ | 58/100 | — | — | — | -1.06% | $856.7M | Benchmark Subject |
| CRVS Corvus Pharmaceuticals Inc. | E | 31/100 | — | — | -35.0% | -2.76% | $860.6M | /crvs-vs-phar → |
| IVA Inventiva S.A. American Depository Shares | C- | 61/100 | — | — | — | +0.54% | $881.3M | /iva-vs-phar → |
| ALMS Alumis Inc. | E | 23/100 | — | — | -35.0% | -3.37% | $891.8M | /alms-vs-phar → |
| OBX Obsidian Therapeutics Inc. | D- | 39/100 | — | — | -35.0% | -0.48% | $896.9M | /obx-vs-phar → |
2. PHAR Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTPharming Group N.V. ADS each representing 10 (PHAR) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $856.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. PHAR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PHAR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Pharming Group N.V. ADS each representing 10 (NASDAQ: PHAR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $12.13 (-1.06% 1D, market cap $856.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PHAR ranks #229 in composite RQD confidence.
How does PHAR compare to CRVS and IVA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PHAR carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CRVS (Corvus Pharmaceuticals Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $860.6M) and IVA (Inventiva S.A. American Depository Shares) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $881.3M). Among the 5-stock peer group, PHAR leads on earnings multiple (N/A) while CRVS leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PHAR?
For Pharming Group N.V. ADS each representing 10 (PHAR), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #229 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PHAR trading relative to its 50-day, 200-day, and 52-week technical levels?
PHAR last traded at $12.13 (-1.06% on volume of 12,429 shares), positioning the stock +13.26% above its 50-day simple moving average ($10.71) and -11.97% below its 200-day simple moving average ($13.78). Across its 52-week range of $9.11 to $21.34, PHAR sits at the 24.7% percentile with a 14-day RSI of 70.1 (OVERBOUGHT (>70)) and an implied next-earnings move of ±7.1% ($11.27 to $12.99).
PHAR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PHAR stock moving today?
Why PHAR Stock slipped -1.06% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.